SlideShare uma empresa Scribd logo
1 de 71
Respiratory System


        NURS156
      Chapter 28 & 29
                                albuterol
 Kapi’olani Community College   corticosteroids
                                for pretty much
                                every resp
Chapter 28 Lower Respiratory problems

 Acute Bronchitis
 Tuberculosis (pgs 569-575)
 Environmental Lung Diseases
 Lung Cancer
 Chest Tubes
Acute Bronchitis               (p 561)



 Inflammation of bronchi usually d/t infection
 Usually caused by virus (rhino or influenza)
 Bacterial cause are common: in smokers
 Acute Exacerbation of Chronic Bronchitis
 (AECB)- an acute infection along w/chronic
 bronchitis                          more sputum from bac

                             supportive care:
                             fluids, rest, meds
M. tuberculosis

      Caused by Mycobacterium tuberculosis
      Remains one of major causes of
      disability and death worldwide
      In 2006, 9.2 million new cases were
      diagnosed and 1.7 million died (NIH,
      2008).                       requires 2years of
      Types of TB include:         multi drug therapy

  
   -Multidrug-Resistant TB (MDR TB)
  
   -Extensively Drug-Resistant TB (XDR TB)
TB in the population

   High rates of TB among HIV population
  Why is this population more vulnerable?
                                 poor compliance of
   Emergence of MDR strains      treatment

  What caused this to happen?    wrong drugs given
                                 because harder to
                                 diagnosis when body does
                                 not produce antigen
                                 immune response
Tuberculosis

Tuberculosis (TB) - communicable airborne
disease caused by M. tuberculosis droplets inhaled
when someone _coughing, sneezing, yelling__
Affects the __ of the lungs first and bacilli not
phagocytized wander through the lymphatic system to
other parts of the lung and body and lay dormant
                                             harbored in
                                             granulona to issolate
                                             the TB when in body

                           active infection may
                           never happen. must
                           be in active stage to
                           transmit
manifestations

   Early stages: no sx
   Active stage: fatigue, malaise, anorexia,
   unexplained wt loss, low-grade fevers,
   and night sweats
   Most common: frequent cough that
   produces white, frothy sputum
   Hemoptysis is seen in advanced cases
   HIV pts may present differently
Diagnostic tests
 PPD- (+) if induration develops at injection
 site 48 to 72 hours after test
 AFB (acid fest bacilli test)
 CXR to view lesions/scars
 Lung Scan
 Bacille Calmette-Guerin Vaccine
 Sputum culture-   confirms diagnosis
                                   only way to
                                   confirm diagnosis
                                   and differenciate
                                   bet ween
                                   pneumonia
First Line TB Drugs
           Isoniazid    side effects:
                        liver toxicity
           Rifampin     and non viral
                        hepatitis

          Ethambutol
         Pyrazinamide

DOT, side effects, prevention to
          active disease
 directly
 observed
 therapy
Nursing concerns
Preventive isolation
Particulate respirators - masks with special
filters that filter droplet nuclei        NEGATIVE
AIRBORN isolation for details check       PRESSURE
                                          ROOM!!
fundamental text
Community Concerns- all contacts with the
patient need to be notified and possibly put on
medications for prevention → 300mg Isonizid
Occupational Lung Disease
            (pg 577-578 & 561)

Caused by inhaling dust or chemicals
Longer exposure= greater damage
Occupational/environmental asthma
Pneumoconiosis: ‘dust in the lungs’
Chemical pneumonitis: exposure from
toxic chemicals
Hypersensitivity pneumonitis/extrinsic
allergic alveolitis: inhaling antigen
                                 cause fibrosis;
                                 scaring
                                 hardened tissue
Lung Cancer
Lung Cancer - affects the epithelium
Four Major Types
 Small cell/Oat cell (SCLC)
NON- Small Cell (NSCLC)
 Squamous/Epidermoid
 Adenocarcinoma
 Large Cell/Undifferentiated
  NSCLC are S-L-O-W growing
Statistics
   Leading cause of cancer or related deaths
   Accounts for 28% of all cancer deaths
   Approx. 172,570 new cases are
   diagnosed each yr
   58% of deaths are in men w/African-
   Americans having the highest rate and
   Hispanics the lowest
   Lung cancer now surpassed breast cancer
   Most common in persons >50 years old
   w/long hx of cigarette smoking
Etiology
  Cigarette smoking-#1 risk factor!
  Responsible for 80% to 90% of all lung
  cancers
  Tobacco smoke contains 60
  The smoke is an irritant
  Ten years after cessation risk of lung
  cancer mortality is reduced 30% to 50%
Diagnostic tests

  CXRs
  CT- most effective noninvasive test
  MRI shows same as CT
  Bronchoscopy or sputum studies
  provide the definitive diagnosis
           usually by dx too late
Lung Cancer S/S

Respiration decreased
Symptoms – Dyspnea, hemoptysis, coughing,
wheezing, fatigue, weight loss, SOB,
sometimes shoulder pain.
Paraneoplastic syndrome
Lung Cancer- treatment

  Staging - TMN system
Treatment Modalities
  RT - mostly for palliation although may be used in
  conjunction with surgery or chemotherapy
  Chemotherapy - works best with small cell
  Surgery: better with non small cell only 25% eligible
  Laser surgery
  Resections - Wedge, Segmental, Lobe, Pneumonectomy
Lung Cancer – nursing care
 Preop
   diagnostic tests
   Education...for pre and post op...what to
 expect, deep breathing for post with practice,
 inspirometer, chest tube expectations.
 Postop
   Monitoring,
   labs,
   DB & C,
   pain management,
   dressings
Chapter 29 Obstructive Pulmonary Diseases


Asthma
COPD- Chronic Obstructive Pulmonary Disease
Chronic Bronchitis
Emphysema
Bronchietasis
Medications
Asthma – Definition

Chronic inflammatory disorder of airways
 Causes airway hyperresponsiveness
  leading to wheezing, breathlessness,
  chest tightness, and cough
Affects about 20 million Americans
Women and African Americans have a 30%
or greater prevalence
Triggers of Asthma
Allergens: 40% of cases
Exercise
Air Pollutants
Occupational Factors
Respiratory Infection
Nose and Sinus Problems ie. Rhinotic
pollops
Drugs and Food Additives
Gastroesophageal Reflux Disease
Emotional Stress
Pathophysiology            thick tenacious
                           (sticky)mucous
                           edema
o Primary response         bronchio spasms

     Hyper-responsivenes
o Inflammatory mediators
o Late-phase response
Factors Causing
Airway
Obstruction
in Asthma




                  Fig. 29-3
Clinical Manifestations
  Unpredictable and variable
  Expiration may be prolonged (3-4x
  longer)
  Wheezing is unreliable to gauge severity
  Cough variant asthma
  feeling of suffocation
  hypoxemia: sx, in rr and pulse, increased
  CO2, decreased O2, restless, anxious,
  inappropriate behavior.
Complications-Status asthmaticus
                                     triggered more
    Status asthmaticus               easily by viral
                                     infections and
 Severe, life-threatening attack    ingestion of
                                     aspirin
unresponsive to usual treatment
   Patient at risk for respiratory failure
 As attack severity ↑, work of breathing
↑, patient tires, and it is harder to
overcome the ↑ resistance to breathing
 Ultimately the patient deteriorates to
hypercapnia (too much CO2) and
hypoxemia
Complications

 Clinical manifestations of status
 asthmaticus result from
  Increased airway resistance from edema
  Mucous plugging
  Bronchospasm
  Respiratory acidosis
Complications of status asthmaticus
Complications of status asthmaticus
 Acute cor pulmonale
 Severe respiratory muscle fatigue leading
  to respiratory arrest
 Death is usually result of respiratory arrest
  or cardiac failure
**Red Flags**
• Heart rate >120 bpm
• Respiratory rate >30 bpm
• Pulsus paradoxus
• Wheezes to silent breath sounds
• Speaks in words not sentences
• O2 sat <90%
• Cant converse
• These signs warrant immediate
 medical intervention to prevent
 respiratory failure
Pulses paradoxus
                           see page 873



Usually during the inspiration phase the
 pulse becomes weaker as one inhales and
 stronger as one exhales. Pulses
 paradoxus is an exaggeration of this
 normal variation in pulse.
This could also indicate other serious
 conditions such as: cardiac tamponade,
 pericarditis, chronic sleep apnea, croup,
 COPD, and asthma
Diagnostic Studies
Detailed history and physical exam
Pulmonary function tests (FEV measuring
how much air u can breath out in one
second)
Peak flow monitoring
Chest x-ray
ABGs
Oximetry
Allergy testing
Blood levels of eosinophils
Sputum culture and sensitivity
Drug Therapy
Long-term control medications
  Achieve and maintain control of persistent
  asthma
Quick-relief medications
  Treat symptoms of exacerbations
Drug Therapy

4 Types of Antiinflammatory Drugs
 Corticosteroids (suppress inflammatory
  response)                       side effects to steroids:
 Mast cell stabilizers           lowers immune response
                                  and healing time
 Leukotriene modifiers            round face and thin skin.
                                  faster metabolism, and
 Monoclonal antibody to IgE      appetite
                                  high glucose levels
Drug Therapy
 Corticosteroids
 Suppress inflammatory response
  Inhaled
  Systemic form
 Mast cell stabilizers
  Inhibit IgE-mediated release of inflammatory
  mast cells
               non-steroidal
Drug Therapy

 Leukotriene modifiers or inhibitors
  Blocks action of leukotrienes- potent
  bronchoconstrictors                 add on therapy to
                                      induce but not
                                      sub for steroids

 Monoclonal antibody to IgE
  ↓ circulating free IgE levels
  Prevents IgE from attaching to mast cells,
  preventing release of chemical mediators
Drug Therapy
3 Types of Bronchodilators
 β2-adrenergic agonists aka rescue drugs
 Methylxanthines – rarely used
 Anticholinergics


β-adrenergic agonists (e.g., albuterol,
metaproterenol)
 Effective for relieving acute bronchospasm
 Onset of action in minutes and duration of 4-8
  hours
 side: tacycard, restlessness
Drug Therapy
 Anticholinergic drugs (e.g., ipratropium,
 atrovent)
  Block action of acetylcholine
  Usually used in combination with a
   bronchodilator
  Most common side effect is dry mouth,
   headache, nervousnes
Patient Teaching
Correct administration of drugs is a major
factor in success
 Inhalation of drugs is preferable to avoid systemic
 side effects
Nursing Management
  Nursing Diagnoses
 Ineffective airway clearance
 Anxiety
 Deficient knowledge

Overall Goals
  Maintain greater than 80% of PEFR
  Have minimal symptoms
  Maintain acceptable activity levels
Collaborative Care
  Desired therapeutic outcomes
   Control or eliminate symptoms
   Attain normal lung function
   Restore normal activities
   Reduce or eliminate exacerbations and side
    effects of medications
   Avoid triggers of acute attacks
   Premedicate before exercising
    Choice of drug therapy depends on symptom severity
Collaborative Care
     Acute asthma episode
 •    O2 therapy should be started
 •    Treatment depends on severity and
      response
 •    Inhaled β-adrenergic agonists by
      metered dose inhaler
 •    Corticosteroids
Collaborative Care
Status asthmaticus
 Most therapeutic measures are the same as for
 acute episode
  ↑ in frequency and dose of bronchodilators
 IV corticosteroids are administered every 4-6
  hours
 Continuous monitoring
 IV fluids - insensible loss of fluids
Nursing Management
Health Promotion

 Teach patient to identify and avoid known
 triggers
 Prompt diagnosis
 Adequate nutrition
 Adequate sleep
 Preventive medications
 Monitoring symptoms
COPD - Overview
 increased resistance secondary to bronchial
  edema, ↑ mucous production, destruction of
  cilia, smooth muscle contraction, or↓ elastic
  recoil, or bronchiolar/alveolar wall damage
 caused by numerous irritants especially
  cigarette smoke which is also a risk factor
COPD - Description
Airflow limitation not fully reversible
 Generally progressive
 Abnormal inflammatory response of lungs to
 noxious particles or gases
Includes
 Chronic bronchitis
 Emphysema
Chronic Bronchitis
 Presence of chronic productive cough for
 3 or more months in each of 2 successive
 years
  Other causes of chronic cough are excluded
Emphysema

Abnormal permanent enlargement of the
air space distal to the terminal
bronchioles
Destruction of bronchioles without
obvious fibrosis
Emphysema - Pathophysiology
Two types
  Centrilobular
  Panlobular
COPD - Etiology
Risk factors
 Cigarette smoking
 Occupational chemicals and dust
 Air pollution
 Infection
 Heredity
 Aging
COPD - Cigarette Smoking
 Effects of nicotine
 Carbon monoxide
 Involuntary smoke exposure


 Effects on respiratory tract
 Increased mucus production
 Hyperplasia of mucus glands
 Lost or decreased ciliary activity
Occupational and Environmental


COPD can develop with intense or
prolonged exposure to
 Dusts, vapors, irritants, or fumes
 High levels of air pollution
 Fumes from indoor heating or cooking
  with fossil fuels
COPD Risk - Factors

Infection
Heredity - α1-Antitrypsin
           deficiency
Aging
COPD - Pathophysiology
Primary process is inflammation
 Inhalation of noxious particles
 Mediators released cause damage to lung
  tissue
 Airways inflamed
 Parenchyma destroyed
Supporting structures of lungs are
destroyed
Pulmonary vascular changes
COPD - Pathophysiology
Common characteristics
 Mucus hypersecretion
 Dysfunction of cilia
 Hyperinflation of lungs
 Gas exchange abnormalities


 Skeletal muscle wasting
COPD - Clinical Manifestations
  Develops slowly
  Diagnosis is considered with
   Cough
   Sputum production
   Dyspnea
   Exposure to risk factors
   Accessory intercostal muscles
   Underweight with adequate caloric intake
COPD - Clinical Manifestations
 Physical examination findings
  Prolonged expiratory phase
  Wheezes
  Decreased breath sounds
  ↑ Anterior-posterior diameter
  Fatigue
                                Dx with pulmonary
  SOB                          function test
COPD - Complications

Exacerbations of COPD                     polycythemia

Acute respiratory failure
Peptic ulcer disease
Depression/anxiety
Cor pulmonale hypertrophy on R side of heart;
                       late manifestation
COPD- Diagnostic Studies

 Diagnosis confirmed by pulmonary
 function tests
 Spirometry—typical findings
 6-minute walk
 ECG
COPD - Collaborative Care
Primary goals of care
 Prevent progression
 Relieve symptoms
 Prevent/treat complications
 Promote patient participation
 Prevent/treat exacerbations
 Improve quality of life and reduce mortality
 risk
COPD- Collaborative Care
 Irritants avoided
 Exacerbations
 Smoking cessation
 Bronchodilators
 corticosteroid therapy
 O2 therapy
               pt with COPD do not
               respond as
               dramatically as pt
               with asthma to O2
COPD - Collaborative Care
 Complications of oxygen therapy
  Combustion     adapted to high CO2 levels
                  if O2 is given decreases
  CO2 narcosis   CO2 concentration which
                  decreases reflex to breath
  O2 toxicity
  Absorption atelectasis
  Infection
COPD - Collaborative Care
Surgical therapy
 Lung volume reduction surgery C-OPD
  Remove 30% of most diseased lung to enhance
  performance of remaining tissue
 Bullectomy
  Used for emphysema
  Large bullae are resected to improve lung function
COPD
Collaborative Care (Cont’d)
 Respiratory and physical therapy
  Aerosol nebulization therapy
  Chest physiotherapy
   Percussion
   Vibration
   Postural drainage



   Pursed-lip breathing          slows RR and extends E


   Effective coughing
COPD - Collaborative Care
 Vibration
  Facilitates movement of secretions to larger
   airways
  Mild vibration tolerated better than percussion
 Flutter mucus clearance device
  Produces vibration in lungs to loosen mucus
   for expectoration
  Handheld device
Lower Respiratory Diseases -
            COPD
Nursing Dx
 Impaired gas exchange
 Ineffective airway clearance
 Activity intolerance
 Anxiety
 Risk for infection
 Imbalanced nutrition
 Sexual dysfunction
 Disturbed sleep pattern
Nursing Management - Planning


Goals

 Knowledge and ability to implement
  long-term regimen
 Overall improved quality of life
Nursing Management
Nursing Implementation


Ambulatory and Home Care
 Most important aspect is teaching
   Pulmonary rehabilitation
   Activity considerations
   Sexual activity
   Sleep
   Psychosocial considerations
disease for life

  Bronchiectasis -
                               longterm antibiotic
                               therapy reser ved for
                               worst case pt.




     ↑ ↑ ↑ mucous production seen in 3 layers →
     clear, cloudy, purulent;
     seen in patients who work with fine particles
     such as flour, aspertame, wheat

hallmark- persistent
and very productive
cough with purulent
sputum up to 500ml of
mucus

Mais conteúdo relacionado

Mais procurados

Bronchial Asthma
Bronchial AsthmaBronchial Asthma
Bronchial AsthmaEneutron
 
Management of asthma and copd
Management  of  asthma and copdManagement  of  asthma and copd
Management of asthma and copdJolly George
 
Asthma medical, nursing managements
Asthma medical, nursing managementsAsthma medical, nursing managements
Asthma medical, nursing managementsReynel Dan
 
Bronchial Asthma: Definition,Pathophysiology and Management
Bronchial Asthma: Definition,Pathophysiology and ManagementBronchial Asthma: Definition,Pathophysiology and Management
Bronchial Asthma: Definition,Pathophysiology and ManagementMarko Makram
 
Pharmacotherapy in bronchial asthma and recent advances
Pharmacotherapy in bronchial asthma and recent advancesPharmacotherapy in bronchial asthma and recent advances
Pharmacotherapy in bronchial asthma and recent advancesDr Resu Neha Reddy
 
Bronchial Asthma
Bronchial AsthmaBronchial Asthma
Bronchial AsthmaNadia Shams
 
management of Bronchial asthma microteaching
management of Bronchial asthma microteachingmanagement of Bronchial asthma microteaching
management of Bronchial asthma microteachingjayaDadhich1
 
Pathophysiology of bronchial asthma f
Pathophysiology of bronchial asthma  fPathophysiology of bronchial asthma  f
Pathophysiology of bronchial asthma fbml08
 
Lecture 5 asthma and copd
Lecture 5  asthma and copdLecture 5  asthma and copd
Lecture 5 asthma and copdMohanad Mohanad
 
Bronchial asthma
Bronchial asthma Bronchial asthma
Bronchial asthma ann geo
 
Asthma and antiasthmatics
Asthma and antiasthmaticsAsthma and antiasthmatics
Asthma and antiasthmaticsDr.Vijay Talla
 
Advances in the Management of Bronchial Asthma
Advances in the Management of Bronchial AsthmaAdvances in the Management of Bronchial Asthma
Advances in the Management of Bronchial AsthmaDr. Waseem A. Siddiqui, MD
 

Mais procurados (20)

Asthma
AsthmaAsthma
Asthma
 
Bronchial Asthma
Bronchial AsthmaBronchial Asthma
Bronchial Asthma
 
Management of asthma and copd
Management  of  asthma and copdManagement  of  asthma and copd
Management of asthma and copd
 
Asthma
Asthma Asthma
Asthma
 
Asthma medical, nursing managements
Asthma medical, nursing managementsAsthma medical, nursing managements
Asthma medical, nursing managements
 
Bronchial Asthma: Definition,Pathophysiology and Management
Bronchial Asthma: Definition,Pathophysiology and ManagementBronchial Asthma: Definition,Pathophysiology and Management
Bronchial Asthma: Definition,Pathophysiology and Management
 
Asthma medications 9
Asthma medications 9Asthma medications 9
Asthma medications 9
 
Pharmacotherapy in bronchial asthma and recent advances
Pharmacotherapy in bronchial asthma and recent advancesPharmacotherapy in bronchial asthma and recent advances
Pharmacotherapy in bronchial asthma and recent advances
 
Bronchial asthma
Bronchial asthmaBronchial asthma
Bronchial asthma
 
Bronchial Asthma
Bronchial AsthmaBronchial Asthma
Bronchial Asthma
 
management of Bronchial asthma microteaching
management of Bronchial asthma microteachingmanagement of Bronchial asthma microteaching
management of Bronchial asthma microteaching
 
Pathophysiology of bronchial asthma f
Pathophysiology of bronchial asthma  fPathophysiology of bronchial asthma  f
Pathophysiology of bronchial asthma f
 
Lecture 5 asthma and copd
Lecture 5  asthma and copdLecture 5  asthma and copd
Lecture 5 asthma and copd
 
Bronchial asthma
Bronchial asthma Bronchial asthma
Bronchial asthma
 
Asthma ppt
 Asthma ppt   Asthma ppt
Asthma ppt
 
Pharmacological Management of Asthma
Pharmacological Management of Asthma Pharmacological Management of Asthma
Pharmacological Management of Asthma
 
Approach to asthma
Approach to asthmaApproach to asthma
Approach to asthma
 
Pharmacotherapy of bronchial asthma
Pharmacotherapy of bronchial asthmaPharmacotherapy of bronchial asthma
Pharmacotherapy of bronchial asthma
 
Asthma and antiasthmatics
Asthma and antiasthmaticsAsthma and antiasthmatics
Asthma and antiasthmatics
 
Advances in the Management of Bronchial Asthma
Advances in the Management of Bronchial AsthmaAdvances in the Management of Bronchial Asthma
Advances in the Management of Bronchial Asthma
 

Semelhante a Respirtory part2

farmer's lung disease
farmer's lung diseasefarmer's lung disease
farmer's lung diseasemaask friend
 
Respiratory Disorders
Respiratory DisordersRespiratory Disorders
Respiratory Disordersguest2379201
 
COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
COPD (CHRONIC  OBSTRUCTIVE  PULMONARY  DISEASE)COPD (CHRONIC  OBSTRUCTIVE  PULMONARY  DISEASE)
COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)kalyan kumar
 
Pneumonia disease of lower respiratory tract
Pneumonia disease of lower respiratory tractPneumonia disease of lower respiratory tract
Pneumonia disease of lower respiratory tractAnjali Parmar
 
6.TUBERCLOSIS in respiratory part of study..pptx
6.TUBERCLOSIS in respiratory part of study..pptx6.TUBERCLOSIS in respiratory part of study..pptx
6.TUBERCLOSIS in respiratory part of study..pptxJuma675663
 
respiratory tract infections
respiratory tract infectionsrespiratory tract infections
respiratory tract infectionspentakota sandhya
 
Respiratory Diseases
Respiratory DiseasesRespiratory Diseases
Respiratory Diseasesshas595
 
Th4 Finley Pulm Infections 08 2
Th4 Finley Pulm Infections 08 2Th4 Finley Pulm Infections 08 2
Th4 Finley Pulm Infections 08 2calvin123
 
Nursing management Lower respiratort problems.pptx
Nursing management Lower respiratort problems.pptxNursing management Lower respiratort problems.pptx
Nursing management Lower respiratort problems.pptxIbrahimkargbo10
 
Respiratory dis. presentation1 for gen path copy (2)
Respiratory dis. presentation1 for gen path   copy (2)Respiratory dis. presentation1 for gen path   copy (2)
Respiratory dis. presentation1 for gen path copy (2)Art Arts
 
MARY TB PRESENTATIONS.pptx
MARY TB PRESENTATIONS.pptxMARY TB PRESENTATIONS.pptx
MARY TB PRESENTATIONS.pptxMuniraMohamed6
 
Tuberculosis 2.pptx
Tuberculosis 2.pptxTuberculosis 2.pptx
Tuberculosis 2.pptxMahimaPaul9
 
GR 6 MUMPS AND NCROUPS.pptx2222222222222
GR 6 MUMPS AND NCROUPS.pptx2222222222222GR 6 MUMPS AND NCROUPS.pptx2222222222222
GR 6 MUMPS AND NCROUPS.pptx2222222222222KelfalaHassanDawoh
 
ASTHMA AND COPD .pptx
ASTHMA AND COPD .pptxASTHMA AND COPD .pptx
ASTHMA AND COPD .pptxBeerDilacshe1
 
Pulmonary tb lec
Pulmonary tb lec Pulmonary tb lec
Pulmonary tb lec DOCTOR WHO
 

Semelhante a Respirtory part2 (20)

farmer's lung disease
farmer's lung diseasefarmer's lung disease
farmer's lung disease
 
Pathology of Pneumonia
Pathology of PneumoniaPathology of Pneumonia
Pathology of Pneumonia
 
Respiratory Disorders
Respiratory DisordersRespiratory Disorders
Respiratory Disorders
 
COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
COPD (CHRONIC  OBSTRUCTIVE  PULMONARY  DISEASE)COPD (CHRONIC  OBSTRUCTIVE  PULMONARY  DISEASE)
COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
 
Pneumonia disease of lower respiratory tract
Pneumonia disease of lower respiratory tractPneumonia disease of lower respiratory tract
Pneumonia disease of lower respiratory tract
 
Respiratory Diseases
Respiratory DiseasesRespiratory Diseases
Respiratory Diseases
 
6.TUBERCLOSIS in respiratory part of study..pptx
6.TUBERCLOSIS in respiratory part of study..pptx6.TUBERCLOSIS in respiratory part of study..pptx
6.TUBERCLOSIS in respiratory part of study..pptx
 
respiratory tract infections
respiratory tract infectionsrespiratory tract infections
respiratory tract infections
 
Respiratory Diseases
Respiratory DiseasesRespiratory Diseases
Respiratory Diseases
 
Th4 Finley Pulm Infections 08 2
Th4 Finley Pulm Infections 08 2Th4 Finley Pulm Infections 08 2
Th4 Finley Pulm Infections 08 2
 
Nursing management Lower respiratort problems.pptx
Nursing management Lower respiratort problems.pptxNursing management Lower respiratort problems.pptx
Nursing management Lower respiratort problems.pptx
 
Farmer’s lung
Farmer’s lungFarmer’s lung
Farmer’s lung
 
Respiratory dis. presentation1 for gen path copy (2)
Respiratory dis. presentation1 for gen path   copy (2)Respiratory dis. presentation1 for gen path   copy (2)
Respiratory dis. presentation1 for gen path copy (2)
 
MARY TB PRESENTATIONS.pptx
MARY TB PRESENTATIONS.pptxMARY TB PRESENTATIONS.pptx
MARY TB PRESENTATIONS.pptx
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Tuberculosis 2.pptx
Tuberculosis 2.pptxTuberculosis 2.pptx
Tuberculosis 2.pptx
 
Pneumonia summary
Pneumonia summaryPneumonia summary
Pneumonia summary
 
GR 6 MUMPS AND NCROUPS.pptx2222222222222
GR 6 MUMPS AND NCROUPS.pptx2222222222222GR 6 MUMPS AND NCROUPS.pptx2222222222222
GR 6 MUMPS AND NCROUPS.pptx2222222222222
 
ASTHMA AND COPD .pptx
ASTHMA AND COPD .pptxASTHMA AND COPD .pptx
ASTHMA AND COPD .pptx
 
Pulmonary tb lec
Pulmonary tb lec Pulmonary tb lec
Pulmonary tb lec
 

Último

Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...JhezDiaz1
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomnelietumpap1
 
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYKayeClaireEstoconing
 
Karra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxKarra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxAshokKarra1
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Mark Reed
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...Postal Advocate Inc.
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPCeline George
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxMaryGraceBautista27
 
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSGRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSJoshuaGantuangco2
 
Judging the Relevance and worth of ideas part 2.pptx
Judging the Relevance  and worth of ideas part 2.pptxJudging the Relevance  and worth of ideas part 2.pptx
Judging the Relevance and worth of ideas part 2.pptxSherlyMaeNeri
 
Q4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxQ4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxnelietumpap1
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Jisc
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4MiaBumagat1
 
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfLike-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfMr Bounab Samir
 

Último (20)

Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptxLEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
 
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...
 
OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choom
 
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITYISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
ISYU TUNGKOL SA SEKSWLADIDA (ISSUE ABOUT SEXUALITY
 
Karra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptxKarra SKD Conference Presentation Revised.pptx
Karra SKD Conference Presentation Revised.pptx
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERP
 
Science 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptxScience 7 Quarter 4 Module 2: Natural Resources.pptx
Science 7 Quarter 4 Module 2: Natural Resources.pptx
 
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTSGRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
GRADE 4 - SUMMATIVE TEST QUARTER 4 ALL SUBJECTS
 
Judging the Relevance and worth of ideas part 2.pptx
Judging the Relevance  and worth of ideas part 2.pptxJudging the Relevance  and worth of ideas part 2.pptx
Judging the Relevance and worth of ideas part 2.pptx
 
Q4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptxQ4 English4 Week3 PPT Melcnmg-based.pptx
Q4 English4 Week3 PPT Melcnmg-based.pptx
 
Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...Procuring digital preservation CAN be quick and painless with our new dynamic...
Procuring digital preservation CAN be quick and painless with our new dynamic...
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4
 
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdfLike-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
Like-prefer-love -hate+verb+ing & silent letters & citizenship text.pdf
 

Respirtory part2

  • 1. Respiratory System NURS156 Chapter 28 & 29 albuterol Kapi’olani Community College corticosteroids for pretty much every resp
  • 2. Chapter 28 Lower Respiratory problems Acute Bronchitis Tuberculosis (pgs 569-575) Environmental Lung Diseases Lung Cancer Chest Tubes
  • 3. Acute Bronchitis (p 561) Inflammation of bronchi usually d/t infection Usually caused by virus (rhino or influenza) Bacterial cause are common: in smokers Acute Exacerbation of Chronic Bronchitis (AECB)- an acute infection along w/chronic bronchitis more sputum from bac supportive care: fluids, rest, meds
  • 4. M. tuberculosis Caused by Mycobacterium tuberculosis Remains one of major causes of disability and death worldwide In 2006, 9.2 million new cases were diagnosed and 1.7 million died (NIH, 2008). requires 2years of Types of TB include: multi drug therapy -Multidrug-Resistant TB (MDR TB) -Extensively Drug-Resistant TB (XDR TB)
  • 5. TB in the population High rates of TB among HIV population Why is this population more vulnerable? poor compliance of Emergence of MDR strains treatment What caused this to happen? wrong drugs given because harder to diagnosis when body does not produce antigen immune response
  • 6. Tuberculosis Tuberculosis (TB) - communicable airborne disease caused by M. tuberculosis droplets inhaled when someone _coughing, sneezing, yelling__ Affects the __ of the lungs first and bacilli not phagocytized wander through the lymphatic system to other parts of the lung and body and lay dormant harbored in granulona to issolate the TB when in body active infection may never happen. must be in active stage to transmit
  • 7. manifestations Early stages: no sx Active stage: fatigue, malaise, anorexia, unexplained wt loss, low-grade fevers, and night sweats Most common: frequent cough that produces white, frothy sputum Hemoptysis is seen in advanced cases HIV pts may present differently
  • 8. Diagnostic tests PPD- (+) if induration develops at injection site 48 to 72 hours after test AFB (acid fest bacilli test) CXR to view lesions/scars Lung Scan Bacille Calmette-Guerin Vaccine Sputum culture- confirms diagnosis only way to confirm diagnosis and differenciate bet ween pneumonia
  • 9. First Line TB Drugs Isoniazid side effects: liver toxicity Rifampin and non viral hepatitis Ethambutol Pyrazinamide DOT, side effects, prevention to active disease directly observed therapy
  • 10. Nursing concerns Preventive isolation Particulate respirators - masks with special filters that filter droplet nuclei NEGATIVE AIRBORN isolation for details check PRESSURE ROOM!! fundamental text Community Concerns- all contacts with the patient need to be notified and possibly put on medications for prevention → 300mg Isonizid
  • 11. Occupational Lung Disease (pg 577-578 & 561) Caused by inhaling dust or chemicals Longer exposure= greater damage Occupational/environmental asthma Pneumoconiosis: ‘dust in the lungs’ Chemical pneumonitis: exposure from toxic chemicals Hypersensitivity pneumonitis/extrinsic allergic alveolitis: inhaling antigen cause fibrosis; scaring hardened tissue
  • 12. Lung Cancer Lung Cancer - affects the epithelium Four Major Types  Small cell/Oat cell (SCLC) NON- Small Cell (NSCLC)  Squamous/Epidermoid  Adenocarcinoma  Large Cell/Undifferentiated  NSCLC are S-L-O-W growing
  • 13. Statistics Leading cause of cancer or related deaths Accounts for 28% of all cancer deaths Approx. 172,570 new cases are diagnosed each yr 58% of deaths are in men w/African- Americans having the highest rate and Hispanics the lowest Lung cancer now surpassed breast cancer Most common in persons >50 years old w/long hx of cigarette smoking
  • 14. Etiology Cigarette smoking-#1 risk factor! Responsible for 80% to 90% of all lung cancers Tobacco smoke contains 60 The smoke is an irritant Ten years after cessation risk of lung cancer mortality is reduced 30% to 50%
  • 15. Diagnostic tests CXRs CT- most effective noninvasive test MRI shows same as CT Bronchoscopy or sputum studies provide the definitive diagnosis usually by dx too late
  • 16. Lung Cancer S/S Respiration decreased Symptoms – Dyspnea, hemoptysis, coughing, wheezing, fatigue, weight loss, SOB, sometimes shoulder pain. Paraneoplastic syndrome
  • 17. Lung Cancer- treatment Staging - TMN system Treatment Modalities RT - mostly for palliation although may be used in conjunction with surgery or chemotherapy Chemotherapy - works best with small cell Surgery: better with non small cell only 25% eligible Laser surgery Resections - Wedge, Segmental, Lobe, Pneumonectomy
  • 18. Lung Cancer – nursing care Preop diagnostic tests Education...for pre and post op...what to expect, deep breathing for post with practice, inspirometer, chest tube expectations. Postop Monitoring, labs, DB & C, pain management, dressings
  • 19. Chapter 29 Obstructive Pulmonary Diseases Asthma COPD- Chronic Obstructive Pulmonary Disease Chronic Bronchitis Emphysema Bronchietasis Medications
  • 20. Asthma – Definition Chronic inflammatory disorder of airways  Causes airway hyperresponsiveness leading to wheezing, breathlessness, chest tightness, and cough Affects about 20 million Americans Women and African Americans have a 30% or greater prevalence
  • 21. Triggers of Asthma Allergens: 40% of cases Exercise Air Pollutants Occupational Factors Respiratory Infection Nose and Sinus Problems ie. Rhinotic pollops Drugs and Food Additives Gastroesophageal Reflux Disease Emotional Stress
  • 22. Pathophysiology thick tenacious (sticky)mucous edema o Primary response bronchio spasms Hyper-responsivenes o Inflammatory mediators o Late-phase response
  • 24. Clinical Manifestations Unpredictable and variable Expiration may be prolonged (3-4x longer) Wheezing is unreliable to gauge severity Cough variant asthma feeling of suffocation hypoxemia: sx, in rr and pulse, increased CO2, decreased O2, restless, anxious, inappropriate behavior.
  • 25. Complications-Status asthmaticus triggered more Status asthmaticus easily by viral infections and  Severe, life-threatening attack ingestion of aspirin unresponsive to usual treatment  Patient at risk for respiratory failure  As attack severity ↑, work of breathing ↑, patient tires, and it is harder to overcome the ↑ resistance to breathing  Ultimately the patient deteriorates to hypercapnia (too much CO2) and hypoxemia
  • 26. Complications Clinical manifestations of status asthmaticus result from  Increased airway resistance from edema  Mucous plugging  Bronchospasm  Respiratory acidosis
  • 27. Complications of status asthmaticus Complications of status asthmaticus  Acute cor pulmonale  Severe respiratory muscle fatigue leading to respiratory arrest  Death is usually result of respiratory arrest or cardiac failure
  • 28. **Red Flags** • Heart rate >120 bpm • Respiratory rate >30 bpm • Pulsus paradoxus • Wheezes to silent breath sounds • Speaks in words not sentences • O2 sat <90% • Cant converse • These signs warrant immediate medical intervention to prevent respiratory failure
  • 29. Pulses paradoxus see page 873 Usually during the inspiration phase the pulse becomes weaker as one inhales and stronger as one exhales. Pulses paradoxus is an exaggeration of this normal variation in pulse. This could also indicate other serious conditions such as: cardiac tamponade, pericarditis, chronic sleep apnea, croup, COPD, and asthma
  • 30. Diagnostic Studies Detailed history and physical exam Pulmonary function tests (FEV measuring how much air u can breath out in one second) Peak flow monitoring Chest x-ray ABGs Oximetry Allergy testing Blood levels of eosinophils Sputum culture and sensitivity
  • 31. Drug Therapy Long-term control medications  Achieve and maintain control of persistent asthma Quick-relief medications  Treat symptoms of exacerbations
  • 32. Drug Therapy 4 Types of Antiinflammatory Drugs  Corticosteroids (suppress inflammatory response) side effects to steroids:  Mast cell stabilizers lowers immune response and healing time  Leukotriene modifiers round face and thin skin. faster metabolism, and  Monoclonal antibody to IgE appetite high glucose levels
  • 33. Drug Therapy Corticosteroids Suppress inflammatory response  Inhaled  Systemic form Mast cell stabilizers  Inhibit IgE-mediated release of inflammatory mast cells non-steroidal
  • 34. Drug Therapy Leukotriene modifiers or inhibitors  Blocks action of leukotrienes- potent bronchoconstrictors add on therapy to induce but not sub for steroids Monoclonal antibody to IgE  ↓ circulating free IgE levels  Prevents IgE from attaching to mast cells, preventing release of chemical mediators
  • 35. Drug Therapy 3 Types of Bronchodilators  β2-adrenergic agonists aka rescue drugs  Methylxanthines – rarely used  Anticholinergics β-adrenergic agonists (e.g., albuterol, metaproterenol)  Effective for relieving acute bronchospasm  Onset of action in minutes and duration of 4-8 hours  side: tacycard, restlessness
  • 36. Drug Therapy Anticholinergic drugs (e.g., ipratropium, atrovent)  Block action of acetylcholine  Usually used in combination with a bronchodilator  Most common side effect is dry mouth, headache, nervousnes
  • 37. Patient Teaching Correct administration of drugs is a major factor in success  Inhalation of drugs is preferable to avoid systemic side effects
  • 38. Nursing Management Nursing Diagnoses Ineffective airway clearance Anxiety Deficient knowledge Overall Goals  Maintain greater than 80% of PEFR  Have minimal symptoms  Maintain acceptable activity levels
  • 39. Collaborative Care Desired therapeutic outcomes  Control or eliminate symptoms  Attain normal lung function  Restore normal activities  Reduce or eliminate exacerbations and side effects of medications  Avoid triggers of acute attacks  Premedicate before exercising  Choice of drug therapy depends on symptom severity
  • 40. Collaborative Care Acute asthma episode • O2 therapy should be started • Treatment depends on severity and response • Inhaled β-adrenergic agonists by metered dose inhaler • Corticosteroids
  • 41. Collaborative Care Status asthmaticus  Most therapeutic measures are the same as for acute episode  ↑ in frequency and dose of bronchodilators  IV corticosteroids are administered every 4-6 hours  Continuous monitoring  IV fluids - insensible loss of fluids
  • 42.
  • 43.
  • 44. Nursing Management Health Promotion Teach patient to identify and avoid known triggers Prompt diagnosis Adequate nutrition Adequate sleep Preventive medications Monitoring symptoms
  • 45. COPD - Overview  increased resistance secondary to bronchial edema, ↑ mucous production, destruction of cilia, smooth muscle contraction, or↓ elastic recoil, or bronchiolar/alveolar wall damage  caused by numerous irritants especially cigarette smoke which is also a risk factor
  • 46. COPD - Description Airflow limitation not fully reversible  Generally progressive  Abnormal inflammatory response of lungs to noxious particles or gases Includes  Chronic bronchitis  Emphysema
  • 47. Chronic Bronchitis Presence of chronic productive cough for 3 or more months in each of 2 successive years  Other causes of chronic cough are excluded
  • 48. Emphysema Abnormal permanent enlargement of the air space distal to the terminal bronchioles Destruction of bronchioles without obvious fibrosis
  • 49. Emphysema - Pathophysiology Two types  Centrilobular  Panlobular
  • 50. COPD - Etiology Risk factors  Cigarette smoking  Occupational chemicals and dust  Air pollution  Infection  Heredity  Aging
  • 51. COPD - Cigarette Smoking Effects of nicotine  Carbon monoxide  Involuntary smoke exposure Effects on respiratory tract  Increased mucus production  Hyperplasia of mucus glands  Lost or decreased ciliary activity
  • 52. Occupational and Environmental COPD can develop with intense or prolonged exposure to  Dusts, vapors, irritants, or fumes  High levels of air pollution  Fumes from indoor heating or cooking with fossil fuels
  • 53. COPD Risk - Factors Infection Heredity - α1-Antitrypsin deficiency Aging
  • 54. COPD - Pathophysiology Primary process is inflammation  Inhalation of noxious particles  Mediators released cause damage to lung tissue  Airways inflamed  Parenchyma destroyed Supporting structures of lungs are destroyed Pulmonary vascular changes
  • 55. COPD - Pathophysiology Common characteristics  Mucus hypersecretion  Dysfunction of cilia  Hyperinflation of lungs  Gas exchange abnormalities  Skeletal muscle wasting
  • 56. COPD - Clinical Manifestations Develops slowly Diagnosis is considered with  Cough  Sputum production  Dyspnea  Exposure to risk factors  Accessory intercostal muscles  Underweight with adequate caloric intake
  • 57. COPD - Clinical Manifestations Physical examination findings  Prolonged expiratory phase  Wheezes  Decreased breath sounds  ↑ Anterior-posterior diameter  Fatigue Dx with pulmonary  SOB function test
  • 58. COPD - Complications Exacerbations of COPD polycythemia Acute respiratory failure Peptic ulcer disease Depression/anxiety Cor pulmonale hypertrophy on R side of heart; late manifestation
  • 59. COPD- Diagnostic Studies Diagnosis confirmed by pulmonary function tests Spirometry—typical findings 6-minute walk ECG
  • 60. COPD - Collaborative Care Primary goals of care  Prevent progression  Relieve symptoms  Prevent/treat complications  Promote patient participation  Prevent/treat exacerbations  Improve quality of life and reduce mortality risk
  • 61. COPD- Collaborative Care Irritants avoided Exacerbations Smoking cessation  Bronchodilators  corticosteroid therapy  O2 therapy pt with COPD do not respond as dramatically as pt with asthma to O2
  • 62. COPD - Collaborative Care Complications of oxygen therapy  Combustion adapted to high CO2 levels if O2 is given decreases  CO2 narcosis CO2 concentration which decreases reflex to breath  O2 toxicity  Absorption atelectasis  Infection
  • 63. COPD - Collaborative Care Surgical therapy  Lung volume reduction surgery C-OPD  Remove 30% of most diseased lung to enhance performance of remaining tissue  Bullectomy  Used for emphysema  Large bullae are resected to improve lung function
  • 64. COPD Collaborative Care (Cont’d) Respiratory and physical therapy  Aerosol nebulization therapy  Chest physiotherapy  Percussion  Vibration  Postural drainage  Pursed-lip breathing slows RR and extends E  Effective coughing
  • 65.
  • 66.
  • 67. COPD - Collaborative Care Vibration  Facilitates movement of secretions to larger airways  Mild vibration tolerated better than percussion Flutter mucus clearance device  Produces vibration in lungs to loosen mucus for expectoration  Handheld device
  • 68. Lower Respiratory Diseases - COPD Nursing Dx  Impaired gas exchange  Ineffective airway clearance  Activity intolerance  Anxiety  Risk for infection  Imbalanced nutrition  Sexual dysfunction  Disturbed sleep pattern
  • 69. Nursing Management - Planning Goals  Knowledge and ability to implement long-term regimen  Overall improved quality of life
  • 70. Nursing Management Nursing Implementation Ambulatory and Home Care  Most important aspect is teaching  Pulmonary rehabilitation  Activity considerations  Sexual activity  Sleep  Psychosocial considerations
  • 71. disease for life Bronchiectasis - longterm antibiotic therapy reser ved for worst case pt. ↑ ↑ ↑ mucous production seen in 3 layers → clear, cloudy, purulent; seen in patients who work with fine particles such as flour, aspertame, wheat hallmark- persistent and very productive cough with purulent sputum up to 500ml of mucus

Notas do Editor

  1. S/S Frequent cough with clear to purulent sputum, have fever, H/A, SOB &amp;#x2013; DOE, Supportive care, uusally a self limiting disease &amp;#x2013; fluids, rest, antiinflammatory meds COPD patients with bronchitis get antibiotics also Will discuss Chronic Bronchitis in Chapter 29
  2. MDR Resistant to two best antibiotics used to cure TB: Isoniazid (INH) and rifampin (RIF) The result? This form of TB is more difficult to tx and requires up to two years of multidrug tx (NIH,2008) XDR A less common for incidence of XMDR TB The TB bacteria have changed enough to be immune to not only the two drugs listed earlier but to most of the alternative drugs used to fight MDR TB such as Fluoroquinolone, amikacin, kanamycin, or capreomycin Extremely challenging to treat! May have to lock up the patient until the disease becomes inactive
  3. TB is missed in HIV patients&amp;#x2013; Misdiagnosis because of lack of s/symptoms are similar and looks like pneumocysitis jiroveci pneumonia Reason for Emergence of TB &amp;#x2013; poor compliance with treatment, no follow up after tx, wrong drugs used Vulnerable populations Poor, underserved, minorities Homeless, inner-city residents, older adults, foreign-born persons, those in institutions (SNF, prison) Immunosuppression for any reason: HIV, CA, increases risk of TB. Additional Risks: Children under five years old IV drug user or ETOH abuser
  4. Coughs, sneezes, speaks or sings Alveoli After TB enters the alveoli, it can spread via the lymphatic system to other lobes, kidneys, epiphysis of bone, cerebral cortex and adrenal glands It is harbored in granuloma which prevent replication (not killed, just islolated). Pt has an infection (inactive). PPD will detect in 2-12 weeks of exposure. .Active infection may never happen. Can not spread to others in the beginning stages. Considered a latent TB infection. TB disease is active, can be transmitted through repeated close contact.
  5. Early &amp;#x2013; no symptoms, inactive no symptoms Active Disease: fatigue, malaise, anorexia, unexplained wt loss, low-grade fevers, and night sweats Sudden acute manifestations: high fever, chills, flu-like symptoms, cough Miliary TB &amp;#x2013; Invasion of the blood stream to other organs
  6. Can be (+) 2 to 12 weeks after initial exposure Once (+), always (+) Assessment of PPD test looks at induration, not redness of injection site. Acid-Fast bacilli &amp;#x2013; AFB &amp;#x2013; found in sputum &amp;#x2013; need 3 cultures over 3 days BCG (vaccine) &amp;#x2013; new- used in high risk areas on children
  7. Treatments - Maybe treated as inpatient - or as outpatient; mainly with a number of medications in 2 phases: 1st phase &amp;#x2192; 4 drugs - Isonizid (INH), rifampin, ethambutol, pyrazinamide; 6 months 2nd phase &amp;#x2192; INH &amp; rifampin or any combination of these drugs Once a week with Directly observed therapy &amp;#x2013; watch the pt. swallow the drug Side effects &amp;#x2013; liver toxicity- non-viral hepatitis Prevention to active disease after exposure &amp;#x2013; Have not converted on PPD test yet &amp;#x2013; Isoniazid QD 6 &amp;#x2013; 9 months
  8. Patients who are admitted with a medical Dx of respiratory disease of unknown origin and/or who have manifestations that may indicate TB, should be isolated in negative pressure flow rooms (keeps air from flowing from the room to the outside) till the Dx is confirmed Nursing planning: Single private room Negative air pressure HEPA masks &amp;#x2013; need to be fitted Hand washing Patient Can have disease relapse after tx
  9. Pneumoconiosis: &amp;#x2018;dust in the lungs&amp;#x2019;. &amp;#x2013; diffuse pulmonary fibrosis Most exposures cause fibrosis &amp;#x2013; scarring after inflammatory response to the irritant Also hypersensitivity and pulmonary edema responses Occupational asthma Coal workers &amp;#x2013; coal dust Farmers &amp;#x2013; moldy hay Hantavirus - inhaling rat dropping particles Silicosis &amp;#x2013; mining for gold, copper, tin, coal, pottery making Latent S/S after many years of exposure. Dyspnea and cough, chest pain can come later Some involve simple skin tests like coccidiomycosis which affects farmers Supportive care, reduce irritants, prevention (wear masks),
  10. Pathogenesis of primary lung cancer is believed to arise from bronchial epithelial cells. These cells grow slowly and may take 8 to 10 years for a tumor to reach 1 cm in size (smallest detectable by CXR) Changes in bronchial system show nonspecific inflammatory changes w/hypersecretion of mucus, desquamation of cells, reactive hyperplasia of basal cells, and metaplasia of normal respiratory epithelium to stratified squamous cells Metastasis primarily by direct extension and via blood/lymph systems Most common sites for metastasis are: liver, brain, bones, scalene lymph nodes, and adrenal glands
  11. Lung cancer now surpassed breast cancer in leading cause of cancer deaths for women. 5 year survival rate is 15 %
  12. Tobacco smoke contains 60 carcinogens along w/carbon monoxide and nicotine which interfere w/normal cell development The smoke is an irritant which causes a change in the bronchial epithelium which usually returns to normal w/cessation Ten years after cessation of smoking risk of lung cancer mortality is reduced 30% to 50% Total risk of developing lung CA is based on total exposure, age of starting to smoke, depth of inhalation, how many cigs per day, type of cig, use of unfiltered cigs, passive exposure from others -home/office Pipes and cigars are included in risk factors Environmental irritants &amp;#x2013; asbestos, radon, nickel Iron, chromates, air pollution, arsenic
  13. CXRs may identify a lung mass or infiltrate and show obstructive features such as atelectasis, pneumonia and metastasis CT- most effective noninvasive test MRI shows same as CT sputum studies Bronchoscopy (biopsy) provide the definitive diagnosis Dx - Unfortunately, by the time the Dx is made, it is often too late especially if it is small cell, because of its rapid growth. CXRs are the least reliable because when seen here, the tumor is usually large and mets has occurred. However, as with any cancer, the earlier caught, the better the prognosis.
  14. Early &amp;#x2013; no symptoms Clinically silent for majority of course Nonspecific and appear in late stages &amp;#x2013; Fatigue, wt loss, hoarseness, N/V, lymph nodes enlarged Chest pain may be present and dyspnea and an auscultatory wheeze if there is a bronchial obstruction Basic problem is that lung tissue cannot exchange O2 and CO2, there is obstruction of air flow &amp; because of the lymphatic system metastasis occurs easily With centrally located tumors, there is usually some degree of coughing, wheezing, stridor and dyspnea; if the vascular nerves are affected there may be shoulder, arm, chest and back pain and hemoptysis is seen with squamous and small cell tumors; Small cell tumors may invade the pericardium &amp; there will be cardiac manifestations, e.g., arrhythmias Paraneoplastic syndrome &amp;#x2013; cancers produce active substances &amp;#x2013; hormones, enzymes, or the body makes them in response to the Cancer. Messes up many body systems and can only be controlled if the tumor is removed.
  15. Staging - TMN system- Oncology lecture Treatment Modalities RT - mostly for palliation although may be used in conjunction with surgery or chemotherapy Chemotherapy - works best with small cell Surgery - best with NSCLC especially if there is no distant metastasis; however only about 25% of patients are candidates and 5 year survival is about 40% Laser surgery &amp;#x2013; remove bronchial obstructions Resections - Wedge, Segmental, Lobe, Pneumonectomy
  16. Preop - PFTs, ABGs, Pre-op education: coughing &amp; breathing exercises, stop smoking, IS, what is a chest tube Interventions: meds, electrolytes, cbc, Postop - the usual, e.g., VS, labs, DB &amp; C, pain management, dressings and CHEST TUBES
  17. Asthma is a chronic inflammatory lung disease that results in recurrent episodes of airflow obstruction, but it is usually reversible. The chronic inflammation causes an increase in airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and cough, particularly at night or in the early morning. Thick mucous is produced from the inflammation. The severity of the attack will affect the patient&amp;#x2019;s alertness, breathlessness, ability to talk, wheeze, use of accessory muscles, RR, P, PaO2, PaCO2
  18. About 40% of cases are related to an allergic response. May be seasonal or year round depending on exposure to allergen Induced or exacerbated after exercise or Pronounced with exposure to cold air Can trigger asthma attacks Cigarette or wood smoke * Vehicle exhaust Elevated ozone levels * Sulfur dioxide Most common form of occupational lung disease from Exposure to diverse agents. Arrive at work well but experience a gradual decline over the course of the day Major precipitating factor of an acute asthma attack &amp;#x2191; inflammation and hyperresponsiveness of the tracheobronchial system Allergic rhinitis and nasal polyps * Large polyps are removed Sinus problems are usually related to inflammation of the mucous membranes Asthma triad: nasal polyps, asthma, and sensitivity to aspirin and NSAIDs Wheezing develops in about 2 hr Sensitivity to salicylate acid - Found in many foods, beverages, and flavorings Food allergies may cause asthma symptoms GERD: mechanism is unknown Reflux of acid could be aspirated into lungs, causing bronchoconstriction Psychologic factors can worsen the disease process Attacks can trigger panic and anxiety
  19. Primary response is chronic inflammation from exposure to allergens or irritants Leading to airway hyperresponsiveness and acute airflow limitations. Inflammatory mediators cause (early-phase response) Vascular congestion Edema formation Production of thick, tenacious mucous Bronchial muscle spasm Thickening of airway walls Late-phase response Occurs within 4-10 hours after initial attack Only occurs in 30%-50% of patients Can be more severe than early-phase and last for 24 hours or more If airway inflammation is not treated or does not resolve, it may lead to irreversible lung damage
  20. Recurrent episodes of wheezing, breathlessness, cough, and tight chest May be abrupt or gradual Lasts minutes to hours Inspiration-expiration ratio of 1:2 to 1:3 or 1:4 Bronchospasm, edema, and mucus in bronchioles narrow the airways. Air takes longer to move out Wheezing is unreliable to gauge severity. Severe attacks may have no audible wheezing. Usually begins upon exhalation &amp;#x2013; exp. wheezing Cough variant asthma Cough is only a symptom and is non-productive. Bronchospasm is not severe enough to cause airflow obstruction Difficulty with air movement can create a feeling of suffocation. Patient may feel increasingly anxious An acute attack usually reveals signs of hypoxemia Restlessness &amp;#x2191; anxiety Inappropriate behavior More signs of hypoxemia &amp;#x2191; pulse and blood pressure
  21. Causes of status asthmaticus Viral illnesses Ingestion of aspirin or other NSAIDs Environmental pollutants or allergen exposure Emotional stress Abrupt discontinuation of drug therapy Abuse of aerosol medication Ingestion of &amp;#x3B2;-adrenergic blockers Wheezing can be heard. IF wheezing is not heard, it could be a life threatening emergency indicating lack of over-inflation of the lungs, inability to exhale, feelings of tightness, Stress on thorax can increase intrathoracic pressure that leads cardiac dysrhythmias,&amp; HTN Beginning stages of attack &amp;#x2013; hypoxemia with hypocapnia, caused by high RR- pH alkalosis. The patient compensates by active diffusion though &amp;#x201C;Dead space areas&amp;#x201D; (Nares, trachea, bronchi). Fatigue causes more CO2 retention but the body has compensated by diffusion so now it has increased capnia. Patient can go rapidiy downhill to resp. failure and need venting to breath.
  22. Patient will usually have asthma symptoms from poor control of disease that has been progressively getting worse over time. Symptoms are the same but are more severe and prolonged. There is anxiety and fear of suffocation, which increases O2 needs. Retractions, nasal flaring, sweating (or not,) hyperinflation seen on x-ray.
  23. Severe muscle fatigue leading to resp. arrest. (cardiac failure)
  24. read
  25. P. 873 for skills A drop in systolic BP during the inspiratory cycle greater than 10mm Hg Normally it does drop but less than 10
  26. (FEV1 Forced expiratory volume in one second) peak expiratory flow rate or FEV1 measured Esinophils for allergy Response Can have asthma and an infection (maybe cause of the asthma)
  27. Medications are divided into two general classifications: long-term&amp;#x2013;control medications to achieve and maintain control of persistent asthma, and (2) quick-relief medications to treat symptoms and exacerbations.
  28. Because chronic inflammation is a primary component of asthma, corticosteroids, which suppress the inflammatory response, are the most potent and effective antiinflammatory medication currently available to treat asthma
  29. Inhaled form is used in long-term control Systemic form to control exacerbations and manage persistent asthma Corticosteroids Reduce bronchial hyperresponsiveness Decrease mucus production Taken on a fixed schedule Mast cell stabilizers - Mast cell stabilizers are nonsteroidal antiinflammatory drugs that inhibit the IgE-mediated release of inflammatory mediators from mast cells and suppress other inflammatory cells (e.g., eosinophils). Long-term administration can prevent and reduce bronchial hyperreactivity Effective in exercise-induced asthma when used 10-20 minutes before exercise
  30. The use of leukotriene modifiers can successfully be used as add-on therapy to reduce (not substitute for) the doses of inhaled corticosteroids. Have both bronchodilator and anti-inflammatory effects Not indicated for acute attacks Used for prophylactic and maintenance therapy Monoclonal - Subcutaneous administration every 2-4 weeks Expensive
  31. Short-acting inhaled &amp;#x3B2;2-adrenergic agonists are the most effective drugs for relieving acute bronchospasm. They are also used for acute exacerbations of asthma and labled Rescue Drugs &amp;#x3B2;2 agonists (albuterol) - act on the smooth muscles and cause dilation, enhance mucous clearance and respiratory muscles; have rapid onset and few side effects &amp;#x2192; tachycardia, tremors, nervousness
  32. &amp;#x3B2;-adrenergic agonists - Anticholinergics (Atrovent) - have greater broncho-dilator effects and fewer side effects than &amp;#x3B2;2 agonists such as:dry mouth, H/A, nervousness; work by blocking cholinergic receptors in the larger airways They block the bronchoconstricting influence of parasympathetic nervous system. Epinephrine &amp;#x2013; racemic
  33. Correct administration of drugs is a major factor in success Using an MDI with a spacer is easier and improves inhalation of the drug DPI (dry powder inhaler) requires less manual dexterity and coordination
  34. Overall Goals No recurrent exacerbations of asthma or decreased incidence of asthma attacks Adequate knowledge to participate in and carry out management
  35. read
  36. Oxygen should be monitored with pulse oximetry or ABGs in severe cases Treatment is based on severity of symptoms and the response to medications. PFTS is one way to check for severity of lung dysfunction. 2 main types of medications: Rescue drugs Albuterol - B-adrenergic agonists by inhalation, MDI or nebulizer Corticosteroids- inhaled or by IV Atrovent every other tx Racemic Epinephrine &amp;#x2013;Status asthmaticus &amp;#x2013; cardiac stimulant, vasopressor, beta angeneric agonist
  37. Acute asthma episode Can be severe enough to require intubation and mechanical ventilation. Used when there is no response to other treatment Louder wheezing may occur in airways that are responding to therapy With progression, normal breath sounds return and wheezing subsides
  38. Click to start on page
  39. Education: Start at time of diagnosis &amp; Integrate through care Self-management is the goal - Tailored to needs of patient Teach patient to identify and avoid known triggers Prompt diagnosis and treatment of upper respiratory infections and sinusitis may prevent exacerbation Seek medical attention for bronchospasm or when severe side effects occur Fluid intake of 2 to 3 L every day Take &amp;#x3B2;-adrenergic agonist 10 to 20 minutes before exercising Peak flow should be monitored daily, and a written action plan should be followed according to results of daily PEFR
  40. Fourth leading cause of death in US More than 50% die within 10 years of diagnosis
  41. Most of the observations, S/s and treatment are the same with emphysema and COPD disease. So they will be discussed as one disease. Emphysema - alveolar sacs are destroyed causing over-distention of the air spaces &amp; obstruction of the airways; have a lot of dyspnea even in the early stages as well as the &amp;#x201C;barrel chest.&amp;#x201D;
  42. Centrilobular (central part of lobule) Dilation and destruction of respiratory bronchioles and pulmonary capillary bed Prominent in upper lobes with little involvement of the alveolar sacs; Panlobular (destruction of whole lobule) Affects respiratory bronchioles, alveolar ducts, and alveolar sacs. Panlobular involves the lower lung &amp;#x2192; alveoli &amp; bronchioles; both seen in smokers It destroys the alveoli in the lower lobes and there is a lot of bleb formation; seen more with patients who have an AAT defect. (Proteinase inhibitors). Blebs (pockets of air) form between the alveolar spaces &amp; bullae form between the lung parenchyma
  43. Smoking: Clinically significant airway obstruction develops in 15% to 20% of smokers 80% to 90% of COPD deaths are related to tobacco smoking Non-modifiable Heredity and aging
  44. Effects of nicotine Stimulates sympathetic nervous system. Increases HR Causes peripheral vasoconstriction. Increases BP and cardiac workload &amp;#x2193; Amount of functional hemoglobin &amp;#x2191; Platelet aggregation. Compounds problems in CAD Effects on respiratory tract Increased mucus production Hyperplasia of mucus glands Lost or decreased ciliary activity Carbon monoxide &amp;#x2193; O2 carrying capacity &amp;#x2191; Heart rate Impaired psychomotor performance and judgment
  45. Recurring infections impair normal defense mechanisms. Intensify pathologic destruction of lung tissue COPD patients are Prone to &amp;#x2191; infection which leads to further mucous production; with each episode of infection the bronchial walls become thickened and inflamed, obstructing the airways during expiration, collapsing the airways, and trapping air leading to a V/Q mismatch, &amp;#x2193; PaO2 and &amp;#x2191; PaCO2 Heredity - &amp;#x3B1;-Antitrypsin (AAT) deficiency Genetic risk factor for COPD. Accounts for &lt;1% to 2% of COPD Some degree of emphysema is common due to physiologic changes of aging lung tissue. Natural changes in the aging lungs Gradual loss of elastic recoil Lungs become rounded and smaller Loss of alveolar supporting structures Decreased number of functional alveoli Decreased arterial O2 levels Thoracic cage changes from osteoporosis and calcification of costal cartilages
  46. Main: Inability to expire air (largely irreversible) is the main characteristic of COPD Supporting structures of lungs are destroyed Air goes in easily but remains in the lungs Bronchioles tend to collapse , trapping air Causes barrel-chest look Pulmonary vascular changes Blood vessels thicken Surface area for diffusion of O2 decreases Increased RR polycythemia
  47. Commonly emphysema and chronic bronchitis coexist Distinguishing symptoms can be difficult with comorbidities Patient get used to having increased Co2 retention. The airways are remodeled, from the inflammatory process and become thickened. Systemic effects of inflammation are skeletal muscle wasting&gt; no known reason&gt; adds to decrease in activity
  48. Intermittent cough is earliest symptom Dyspnea usually prompts medical attention Occurs with exertion in early stages Present at rest with advanced disease Causes chest breathing Use of accessory and intercostal muscles Inefficient type of breathing Characteristically underweight with adequate caloric intake Chronic fatigue
  49. The diagnosis of COPD is confirmed by pulmonary function tests. Goals of the diagnostic workup are to confirm the diagnosis of COPD via spirometry, evaluate the severity of the disease, and determine the impact of disease on the patient&amp;#x2019;s quality of life. When the FEV1/FVC ratio is less than 70%, it suggests the presence of obstructive lung disease. (useful in differentiating between obstructive and restrictive pulmonary dysfunction.) Patients seem to have an easy time getting a breath in, but have difficulty getting it out. This causes the prolonged exp. phase.
  50. Exacerbations of COPD are signaled by a change in the patient&amp;#x2019;s usual dyspnea, cough, and/or sputum that is different than the usual daily patterns. These flares require changes in management. Frequent exacerbations associated with poorer outcomes. Primary causes are: Tracheobronchial infection, Air pollution A respiratory failure: Caused by Overuse of sedatives, benzodiazepines, and opioids &amp;#x2013; suppress ventilatory drive Surgery or severe, painful illness involving chest or abdomen Discontinuing bronchodilator or corticosteroid medication Complications: Polycythemia-compensation for hypoxemia GERD: Increased incidence with COPD patients who chronically retain CO2. Commonly in duodenum and painless Depression may be four times more likely for COPD patients Anxiety complicates treatment for symptoms of : Dyspnea &amp; Hyperventilation Cor pulmonale is hypertrophy of the right side of the heart, with or without heart failure, resulting from pulmonary hypertension and is a late manifestation of chronic pulmonary heart disease. HTN of the pulmonary vasculature increases the pressure in the R atrium. This leads to hypertrophy of the right side of the heart. S &amp; S - peripheral edema, hepatomegaly, splenomegaly, JVD Treatments - diuretics and digoxin
  51. The diagnosis of COPD is confirmed by pulmonary function tests. Goals of the diagnostic workup are to confirm the diagnosis of COPD via spirometry, evaluate the severity of the disease, and determine the impact of disease on the patient&amp;#x2019;s quality of life. Diagnosis confirmed by pulmonary function tests. When the FEV1/FVC ratio is less than 70%, it suggests the presence of obstructive lung disease. Chest x-rays, spirometry, history, and physical examination are also important in the diagnostic workup 6-minute walk test to determine O2 desaturation in the blood with exercise ECG can show signs of right ventricular failure
  52. read
  53. Irritants should be evaluated and avoided Exacerbations treated promptly Smoking cessation Most effective intervention Accelerated decline in pulmonary function slows and usually improves Drug therapy Bronchodilators - Relaxes smooth muscle in the airway - Improves ventilation of the lungs Drug therapy Inhaled corticosteroid therapy - Used for moderate-to-severe cases Although patients with COPD do not respond as dramatically as those with asthma to bronchodilator therapy, a reduction in dyspnea and an increase in FEV1 are usually achieved. Presently no drug modifies the decline of lung function with COPD. O2 therapy is used to Reduce work of breathing *Maintain PaO2 Reduce workload on heart
  54. Chronic O2 therapy from O2 toxicity can lead to ARDS. Amount administered should just be enough to maintain PaO2 within normal or acceptable range. O2 therapy above 50% is considered toxic. Periodic reevaluations are necessary to determine duration of use CO2 narcosis &amp;#x2013; Normally co2 accumulation is the major stimulent of the respiratory center. Some patients develop a tolerance for high Co2 levels. Anyway you never deprive a patient of O2 if needed. The lowest level should be used. Many COPD patients require high flow rates and higher concentrations to live. ABG&amp;#x2019;s determine the rate and concentration of O2
  55. Surgical therapy Lung transplantation Single lung&amp;#x2014;most common due to donor shortages Prolongs life Improves functional capacity Enhances quality of life
  56. Breathing retraining - Decreases dyspnea, improves oxygenation, and slows respiratory rate Pursed-lip breathing is a technique that is used to prolong exhalation and thereby prevent bronchiolar collapse and air trapping. Often instinctively patients will perform this technique. Effective coughing - Main goals Conserves energy Reduces fatigue Facilitates removal of secretions
  57. Click to start on page
  58. Pulmonary rehabilitation &amp;#x2013; p 652-53 Increases exercise performance Reduces dyspnea Improves quality of life Activity considerations Exercise training leads to energy conservation In upper extremities it may improve muscle function and reduce dyspnea Modify ADLs to conserve energy Walk 15 to 20 minutes a day at least three times a week Adequate rest should be allowed Sexual activity Plan when breathing is best Do not assume dominant position or prolong foreplay Sleep Can be difficult because of medications, postnasal drip, or coughing Nasal saline sprays, decongestants, or nasal steroid inhalers can help
  59. Bronchiectasis is characterized by permanent, abnormal dilation of one or more large bronchi. The pathophysiologic change that results in dilation is destruction of the elastic and muscular structures supporting the bronchial wall. The hallmark of bronchiectasis is persistent or recurrent cough with production of large amounts of purulent sputum, which may exceed 500 ml/day. Bronchiectasis is difficult to treat. Therapy is aimed at treating acute flare-ups and preventing decline in lung function. Antibiotics are the mainstay of treatment and are often given empirically, but attempts are made to culture the sputum. Long-term suppressive therapy with antibiotics is reserved for those patients who have symptoms that recur a few days after stopping antibiotics. An important nursing goal is to promote drainage and removal of bronchial mucus.